Apricus Biosciences, a biopharmaceutical company, completed the merger with Seelos Therapeutics, a clinical-stage biopharmaceutical company. Financial terms were not disclosed. “The mutual support for this transaction by both Apricus’ and Seelos’ shareholders was evident, underscoring a commitment to a long-term growth strategy to become a fully-integrated multi-platform CNS company and create value from a diversified pipeline of late-stage clinical assets in areas of high unmet need. The closing of this merger enables us to grow our operations and execute on our clinical development goals. As we enter this next stage of growth as a publicly traded company, we have built a strong foundation with a team of established industry leaders and a robust pipeline of potentially transformative product candidates with proven mechanisms of action, including several late-stage assets. The merger builds upon our vision to develop, advance and commercialize innovative therapeutics for patients with CNS disorders. We look forward to establishing a leadership position in the field of neurologic disorders, growing our team, driving long-term shareholder value, and bringing to market therapies for patients who currently have no viable treatment options," Raj Mehra, Seelos Therapeutics Chairman and CEO.